Generated by AI
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Supernus Pharmaceuticals, Inc. markets therapies for neurological and psychiatric conditions such as attention-deficit hyperactivity disorder, epilepsy, migraine, Parkinson’s disease-related symptoms, cervical dystonia, chronic sialorrhea, and postpartum depression. Its current portfolio includes branded medicines used in neurology and psychiatry, with products sold primarily in the United States through specialty commercial channels. The company also maintains research and development programs aimed at advancing new CNS treatments and strengthening its neuroscience portfolio. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. plays a notable role in the specialty pharmaceutical market by addressing a broad range of chronic and complex disorders affecting the central nervous system.
Website9715 Key West Avenue
Rockville, MD, 20850
United States
The latest articles about SUPN.
Supernus Pharmaceuticals has delivered a 75.7% gain over the past three years, even though the stock is down year to date, which naturally puts the current share price under the microscope. The immediate question for you as an investor is whether that price is still grounded in what the business is actually generating in sales. The 75.7% return over three years puts real weight on the question of whether Supernus Pharmaceuticals' current valuation can still be explained by its revenue...
Summary of Aug 3's posts. Generated by AI.
Summary of Aug 16's posts. Generated by AI.
Summary of Jun 1's posts. Generated by AI.
Summary of Aug 3's posts. Generated by AI.
Investors talking about SUPN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.